Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain

Members update

Climacteric E-alert - Volume 20, Number 2; 
Langer's insights on the WHI study: unbiased evaluation and behind the scene facts; 
Cognitive aging in midlife women: is it real?; 
New information technologies in medical practice; 
Our Menopause World March 2017; 
Risk of recurrent venous thromboembolism in hormone therapy users; 
Misclassification rates in breast histopathology biopsies: how can they be lowered?; 
Menopause and work; 
Cosmetics and women's health; 
Endocrine-disrupting chemicals – are they of concern and can we really reduce our exposure; 
NAMS Menopause Care; 
HRT, dry eyes and other ocular manifestations; 

Articles available to Members as well as access to the AMS journal Changes, NAMS First to Know, Congress Abstracts, AGM Minutes, Award Winners and more...

Log on to view.
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Changes Magazine 

Changes  Volume 1: 2017  

Climacteric

Climacteric E-alert - Volume 20, Number 2

Studies Published

NAMS

NAMS Menopause Care Updates

The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65  

IMS Our Menopause World 

Our Menopause World March 2017

IMS Menopause Live 

All articles from IMS Live

Cognitive aging in midlife women: is it real? 
Cognitive aging has become an important issue because of increased life expectancy in women. Cognitive complaints are common during midlife, as part of the climacteric syndrome. By using data from a longitudinal observational s...      

New information technologies in medical practice 
New information technologies have entered medical practice. The role of the internet has frequently been investigated regarding advantages and disadvantages. In August, Medscape surveyed 1423 health-care providers, including 847 ...  

Risk of recurrent venous thromboembolism in hormone therapy users
One of the main issues discussed in relation to postmenopausal hormone therapy (HT) is the risk for venous thromboembolic (VTE) events. In fact, this safety aspect of HT use is probably the only significant one in healthy women younger than 60 or during the first decade of use. A history of VTE usually deters physicians from prescribing HT as these women have anyway a higher risk for recurrent VTE in the future. Is this true also for women who were already using HT when the index VTE occurred? 

Misclassification rates in breast histopathology biopsies: how can they be lowered?
Because misclassification of breast biopsies is relatively common, and no prior study had analyzed strategies for reducing error, the recent Elmore study is timely [1]. Here, 12 different strategies for acquiring second opinions were compared in order to help define which strategies worked best to reduce misclassification errors. The authors systematically tested whether and which pathology classification affected the best strategic choice for: invasive breast cancer, ductal carcinoma in situ (DCIS), atypia, proliferative without atypia, or benign without atypia. Also analyzed was the influence of the perceived case difficulty, the pathologists’ clinical volumes, and local institutional policy. 

Content Updated April 2017

PrintEmail

Search

Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain